Abstract | PURPOSE: METHODS: This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA. RESULTS: Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted. CONCLUSIONS: Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
|
Authors | Giulio Ferrari, Mohammad H Dastjerdi, Andre Okanobo, Sheng-Fu Cheng, Francisco Amparo, Nambi Nallasamy, Reza Dana |
Journal | Cornea
(Cornea)
Vol. 32
Issue 7
Pg. 992-7
(Jul 2013)
ISSN: 1536-4798 [Electronic] United States |
PMID | 23407316
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Ophthalmic Solutions
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Ranibizumab
|
Topics |
- Administration, Topical
- Adult
- Aged
- Angiogenesis Inhibitors
(administration & dosage)
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Blood Vessels
(drug effects, pathology)
- Cornea
(blood supply)
- Corneal Neovascularization
(drug therapy, physiopathology)
- Female
- Humans
- Intraocular Pressure
(physiology)
- Male
- Middle Aged
- Ophthalmic Solutions
- Prospective Studies
- Ranibizumab
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
|